Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Current Deferred Revenue (2016 - 2022)

Historic Current Deferred Revenue for Myriad Genetics (MYGN) over the last 12 years, with Q3 2022 value amounting to $200000.0.

  • Myriad Genetics' Current Deferred Revenue fell 9826.09% to $200000.0 in Q3 2022 from the same period last year, while for Sep 2022 it was $200000.0, marking a year-over-year decrease of 9826.09%. This contributed to the annual value of $5.2 million for FY2021, which is 8409.79% down from last year.
  • Per Myriad Genetics' latest filing, its Current Deferred Revenue stood at $200000.0 for Q3 2022, which was down 9826.09% from $300000.0 recorded in Q2 2022.
  • Myriad Genetics' 5-year Current Deferred Revenue high stood at $32.8 million for Q2 2020, and its period low was $200000.0 during Q3 2022.
  • For the 5-year period, Myriad Genetics' Current Deferred Revenue averaged around $10.2 million, with its median value being $2.6 million (2018).
  • In the last 5 years, Myriad Genetics' Current Deferred Revenue surged by 143809.52% in 2020 and then tumbled by 9867.26% in 2022.
  • Myriad Genetics' Current Deferred Revenue (Quarter) stood at $2.4 million in 2018, then skyrocketed by 50.0% to $3.6 million in 2019, then skyrocketed by 808.33% to $32.7 million in 2020, then tumbled by 84.1% to $5.2 million in 2021, then tumbled by 96.15% to $200000.0 in 2022.
  • Its Current Deferred Revenue stands at $200000.0 for Q3 2022, versus $300000.0 for Q2 2022 and $700000.0 for Q1 2022.